ArticleIndian journal of orthopaedics2022
Aggressive Presentation and Rapid Progression of Osteonecrosis of the Femoral Head After COVID-19.
Article in Indian journal of orthopaedics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Impact of COVID-19 on the Development of Femoral Head Avascular Necrosis: A Systematic Review.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Osteonecrosis as a manifestation of Long-COVID Syndrome: a systematic review.Musculoskeletal surgery · 2025Pooled it
- Femoral head avascular necrosis in COVID-19 survivors: a systematic review.Rheumatology international · 2023Pooled it
- Autologous bone marrow mononuclear cell transplantation for osteonecrosis of the femoral head in post-covid-19 syndrome: A case series.Regenerative therapy · 2025Article
- [Atraumatic necrosis of the femoral head].Orthopadie (Heidelberg, Germany) · 2025Review
- Exploring the Association Between COVID-19 and Avascular Necrosis: A Systematic Review.Cureus · 2025Review
- Article
- PDGF-BB improves cortical bone quality through restoring the osteogenic microenvironment in the steroid-associated osteonecrosis of rabbits.Journal of orthopaedic translation · 2025Article
- Characteristics of osteonecrosis of the femoral head after COVID-19 steroid treatment compared to steroid-associated osteonecrosis.BMC musculoskeletal disorders · 2025Article
- Is there an Increase in Total Hip Arthroplasty Due to Osteonecrosis of Femoral Head After Covid-19 Pandemic?: A Retrospective Study Among Patients in Central Karnataka, India.Journal of orthopaedic case reports · 2025Article
- Corticosteroid-associated osteonecrosis of the femoral head in an 87-year-old patient following treatment for COVID-19-associated pneumonia: A case report.Skeletal radiology · 2024Article
- Spontaneous Osteonecrosis of Knee: A Complication of COVID-19 or An Iatrogenic Side Effect of Steroid Use?Journal of orthopaedic case reports · 2024Article
- Is COVID-19 an independent risk factor for the development of avascular necrosis of the hip? A retrospective study to evaluate the factors associated with avascular necrosis of the hip in patients who had COVID-19 infection.International orthopaedics · 2024Article
- Two Cases of COVID-Related Osteonecrosis of the Jaws: A New and Worrying Entity Is Emerging.World journal of plastic surgery · 2024Article
- Effects of Thymoquinone on Urotensin-II and TGF-β1 Levels in Model of Osteonecrosis in Rats.Medicina (Kaunas, Lithuania) · 2023Article
- Article
- Post-COVID steroid induced avascular necrosis of the jaw: Emerging challenge in India.Oral surgery, oral medicine, oral pathology and oral radiology · 2023Article
- Dose-Response Meta-Analysis of Corticosteroid Effects in SARS Outbreak: A Model for Risk Stratification and Screening Strategy for Osteonecrosis of Femoral Head Post-Corticosteroid Therapy for COVID-19.Life (Basel, Switzerland) · 2023Review
- Article
- Screening for Femoral Head Osteonecrosis Following COVID-19: Is It Worth It?The archives of bone and joint surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aim to report the consecutive patients diagnosed with osteonecrosis of femoral head (ONFH) following recovery from COVID-19 disease and elucidate the unique features of ONFH associated with COVID-19. Methods: Consecutive 22 patients (39 hips) recovered from COVID-19 and presented with ONFH from November 2020 to October 2021 were included. All the patients received corticosteroids as a supportive treatment during COVID-19. Patients were classified into two types based on the type of presentation, namely classic ONFH and rapidly destructive coxarthrosis (RDC) depending on radiographs, MRI, inflammatory markers and hip aspiration findings. Harris hip score was used to evaluate the functional outcome before and after treatment. Results: The mean time to diagnose of ONFH from the onset of hip symptoms was 39.3 days (range 10-90 days). The average duration of onset of hip symptoms after COVID 19 infection was 7.5 months (range 3 - 11 months). The average cumulative dose of methylprednisolone equivalent was 811 mg (range 200-2100 mg) and the average duration of steroid intake was 2.8 weeks. There was significant elevation in the inflammatory markers in RDC group compared to classic ONFH ( Conclusion: ONFH after COVID-19 can have a varied presentation. While the most common presentation is like classical ONFH, some patients can have an acute and aggressive presentation with rapid destruction. They have features like elevated serological markers and extensive periarticular bone and soft tissue edema. A low cumulative dose of steroids in our patients suggests that the COVID-19-associated vasculitis may play a role in the pathogenesis of ONFH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.